Rheumatoid Arthritis Management: Turning Treatment Failures into Successes

In this video module, Gregg J. Silverman, MD, and Sergio Schwartzman, MD, discuss approaches to integrating the latest ACR recommendations for initiating treatment and addressing treatment failures in rheumatoid arthritis.
Gregg J. Silverman, MD
Program Director
Sergio Schwartzman, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: June 7, 2016 Expiration: June 6, 2017

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement a treat-to-target strategy that includes timely initiation of DMARD therapy in treatment-naive patients with newly diagnosed rheumatoid arthritis
  • Apply evidence-based treatment options in patients with moderate to severe rheumatoid arthritis
  • Recognize treatment failures in patients with rheumatoid arthritis and choose guideline recommended options to achieve clinical response and remission

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Gregg J. Silverman, MD

Professor of Medicine and Pathology
NYU School of Medicine
New York, New York

Gregg J. Silverman, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb and Pfizer and has received fees for non-CME/CE activities from Bristol-Myers Squibb and Genentech.


Sergio Schwartzman, MD

Franchellie M. Cadwell Associate Professor of Medicine
Weill Medical College of Cornell University
Hospital for Special Surgery
NewYork-Presbyterian Hospital
New York, New York

Sergio Schwartzman, MD, has disclosed that he has received consulting fees from AbbVie, Crescendo, Discus Analytics, Epirus, Genentech, Hospira, Janssen, National Psoriasis Foundation, Novartis, Pfizer, and Regeneron and has served on speaker bureaus for AbbVie, Crescendo, Genentech, Hospira, Janssen, Novartis, and Pfizer.


Andrew D. Bowser, ELS, CHCP

Director, Educational Strategy and Outcomes

Andrew D. Bowser, ELS, CCMEP, has no real or apparent conflicts of interest to report.
Megan K. Murphy, PhD

Scientific Director

Megan Murphy, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for rheumatologists, internists, primary care physicians, and other clinicians who manage patients with rheumatoid arthritis.


The goal of this activity is to improve participants’ knowledge, confidence and competence in the management of patients with rheumatoid arthritis.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 07, 2016, through June 06, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

CCO faculty Dr Kenneth Calamia discusses the clinical features of Behçet’s disease and how to weigh symptoms when making a diagnosis

person default Kenneth T. Calamia, MD Released: January 28, 2020

Gary R. Lichtenstein, MD, and Uma Mahadevan, MD: comparable efficacy, risks, and real-world data on biologic and small molecules therapies for moderate to severe UC

Gary Lichtenstein Headshot Gary R. Lichtenstein, MD Uma Mahadevan, MD Released: January 24, 2020

CCO faculty Dr. Jonathan Kay’s viewpoint on data from 2019 ACR/ARP on novel approaches for treatment of RA

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 9, 2020 Expiration: January 8, 2021

CCO faculty Dr. Yusuf Yazici on treating mucocutaneous manifestations such as oral ulcers in Behçet’s: apremilast, colchicine, dapsone, pentoxifylline, thalidomide

Yusuf Yazici, MD Released: December 16, 2019
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Supported by an educational grant from
Lilly USA, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?